Paper Details 
Original Abstract of the Article :
The HOPE TIPS study assessed the practicality and tolerability of ramipril titration to a target dose of 10 mg (as achieved in definitive efficacy studies) in a clinical practice setting. 3881 patients at high cardiovascular risk (HOPE study criteria) were recruited in primary and specialist care se...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/s10557-005-1375-1

データ提供:米国国立医学図書館(NLM)

HOPE TIPS: Translating Ramipril Titration into Practice

Navigating the vast and complex desert of cardiovascular disease research can feel daunting. This study, like a skilled camel guide leading a caravan across a challenging terrain, focuses on the practical application of ramipril titration in a real-world setting. The HOPE TIPS study aimed to assess the feasibility and tolerability of titrating ramipril to a target dose of 10 mg in patients at high cardiovascular risk. The study, conducted in nine countries with over 400 researchers, involved over 3,800 participants with a mean age of 64 years. The results demonstrate that ramipril titration to 10 mg daily is achievable in a large majority of patients, with good tolerability and a manageable side effect profile. This is particularly notable considering the high cardiovascular risk of the study population.

Ramipril Titration: Achieving Optimal Dosage in Clinical Practice

This study, like a well-stocked oasis providing sustenance and relief, demonstrates the practicality of ramipril titration in a real-world setting. The results show that a significant proportion of patients, even those at high cardiovascular risk, can safely achieve a therapeutic dose of 10 mg daily. This highlights the importance of individualized treatment approaches and the need to tailor medication regimens to the specific needs of each patient. By understanding the feasibility and tolerability of ramipril titration, clinicians can optimize treatment strategies and improve patient outcomes.

Managing Cardiovascular Risk: The Importance of Ramipril Titration

In the vast and unforgiving desert of cardiovascular disease, effective treatment strategies are paramount. This study, like a cool breeze in a hot desert, offers a refreshing perspective on ramipril titration, demonstrating its practical application in a diverse population. The results suggest that ramipril titration can be safely and effectively implemented in real-world clinical practice, potentially leading to improved cardiovascular health and reduced risks for those at high cardiovascular risk. This study, like a vital well in a parched landscape, provides hope for better management of cardiovascular disease and improved patient outcomes.

Dr. Camel's Conclusion

Navigating the desert of cardiovascular disease requires a reliable guide, and this study, like a skilled camel guide, has demonstrated the efficacy and practicality of ramipril titration. By understanding the feasibility and tolerability of this treatment approach, clinicians can provide optimal care for patients at high cardiovascular risk, potentially leading to improved health outcomes.
Date :
  1. Date Completed 2006-01-18
  2. Date Revised 2016-10-20
Further Info :

Pubmed ID

16142597

DOI: Digital Object Identifier

10.1007/s10557-005-1375-1

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.